SLC5A2 and type 2 diabetes mellitus: Sodium glucose co-transporter-2 Inhibitor (SGLT2-inhibitor) are a newer class of oral hypoglycemic agents that have shown to be effective as monotherapy and as an add-on treatment for T2DM with significant add-on benefit regarding body weight and systolic blood pressure reduction.